Literature DB >> 26913516

Cardiac pacing strategies and post-implantation risk of atrial fibrillation and heart failure events in sinus node dysfunction patients: a collaborative analysis of over 6000 patients.

Shaojie Chen1,2, Zhenglong Wang3, Marcio Galindo Kiuchi4,5, Bruno Rustum Andrea6, Mitchell W Krucoff7, Shaowen Liu8, Helmut Pürerfellner9.   

Abstract

BACKGROUND: Pacing-modes selection in sinus-node-dysfunction (SND) patients continues to be a subject of debate. Atrial fibrillation (AF) and cardiac dysfunction remain significant problems following cardiac-pacing therapy. Prevention of these complications is of clinical relevance.
METHODS: We performed a collaborative pooled-analysis of randomized trials (RCT) to evaluate the effect of currently available pacing strategies on the risk of post-implantation AF and heart failure events (HF) in SND patients. The primary endpoint was a composite AF and HF events.
RESULTS: Ten RCTs (n = 6639, male 57 %, median follow-up 2.5 years) were included. The pooled-analysis was stratified into two subsets [single chamber atrial pacing (AAI) vs. dual chamber pacing (DDD), and minimal ventricular pacing (MinVP) vs. DDD]. No significant difference was observed in the AAI vs. DDD subset regarding the primary outcome (P = 0.83). Notably, the mean percentage of ventricular-pacing in the MinVP group was 6.5 vs. 77.4 % in the DDD group (P < 0.05), and MinVP was associated with a substantially reduced risk of composite AF and HF (OR 0.66, P = 0.007) in patients receiving pacemaker as primary treatment. However, in the long-term paced patients scheduled for device replacement, there was no significant difference in the rate of primary endpoint between MinVP vs. DDD groups (P > 0.05).
CONCLUSIONS: These results support MinVP over conventional DDD for SND patients who received pacemaker as primary treatment in improving the clinical outcome. For patients who already had chronic ventricular-pacing and impaired cardiac function, a device update to MinVP algorithm may exert no favorable effect on the cardiac performance.

Entities:  

Keywords:  Atrial fibrillation; Cardiac pacing; Heart failure; Outcome; Randomized trials; Sinus node dysfunction

Mesh:

Year:  2016        PMID: 26913516     DOI: 10.1007/s00392-016-0973-1

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  41 in total

1.  Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators.

Authors:  S J Connolly; C R Kerr; M Gent; R S Roberts; S Yusuf; A M Gillis; M H Sami; M Talajic; A S Tang; G J Klein; C Lau; D M Newman
Journal:  N Engl J Med       Date:  2000-05-11       Impact factor: 91.245

2.  Relationship between pacemaker dependency and the effect of pacing mode on cardiovascular outcomes.

Authors:  A S Tang; R S Roberts; C Kerr; A M Gillis; M S Green; M Talajic; S Yusuf; H Abdollah; M Gent; S J Connolly
Journal:  Circulation       Date:  2001-06-26       Impact factor: 29.690

3.  Effect of pacing mode on health-related quality of life in the Canadian Trial of Physiologic Pacing.

Authors:  David Newman; Ching Lau; Anthony S L Tang; Jane Irvine; Miney Paquette; Kirsten Woodend; Paul Dorian; Michael Gent; Charles Kerr; Stuart J Connolly
Journal:  Am Heart J       Date:  2003-03       Impact factor: 4.749

4.  Canadian Trial of Physiological Pacing: Effects of physiological pacing during long-term follow-up.

Authors:  Charles R Kerr; Stuart J Connolly; Hoshiar Abdollah; Robin S Roberts; Michael Gent; Salim Yusuf; Anne M Gillis; Anthony S L Tang; Mario Talajic; George J Klein; David M Newman
Journal:  Circulation       Date:  2004-01-05       Impact factor: 29.690

5.  Regional myocardial blood flow in patients with sick sinus syndrome randomized to long-term single chamber atrial or dual chamber pacing--effect of pacing mode and rate.

Authors:  J C Nielsen; M Bøttcher; T T Nielsen; A K Pedersen; H R Andersen
Journal:  J Am Coll Cardiol       Date:  2000-05       Impact factor: 24.094

6.  AV block and changes in pacing mode during long-term follow-up of 399 consecutive patients with sick sinus syndrome treated with an AAI/AAIR pacemaker.

Authors:  L Kristensen; J C Nielsen; A K Pedersen; P T Mortensen; H R Andersen
Journal:  Pacing Clin Electrophysiol       Date:  2001-03       Impact factor: 1.976

7.  A randomized comparison of atrial and dual-chamber pacing in 177 consecutive patients with sick sinus syndrome: echocardiographic and clinical outcome.

Authors:  Jens C Nielsen; Lene Kristensen; Henning R Andersen; Peter T Mortensen; Ole L Pedersen; Anders K Pedersen
Journal:  J Am Coll Cardiol       Date:  2003-08-20       Impact factor: 24.094

8.  Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction.

Authors:  Michael O Sweeney; Anne S Hellkamp; Kenneth A Ellenbogen; Arnold J Greenspon; Roger A Freedman; Kerry L Lee; Gervasio A Lamas
Journal:  Circulation       Date:  2003-06-02       Impact factor: 29.690

9.  The effect of atrial pacing therapies on atrial tachyarrhythmia burden and frequency: results of a randomized trial in patients with bradycardia and atrial tachyarrhythmias.

Authors:  Michael A Lee; Richard Weachter; Scott Pollak; Mark S Kremers; Ajay M Naik; Russell Silverman; Joann Tuzi; Wayne Wang; Linda J Johnson; David E Euler
Journal:  J Am Coll Cardiol       Date:  2003-06-04       Impact factor: 24.094

10.  Ventricular pacing or dual-chamber pacing for sinus-node dysfunction.

Authors:  Gervasio A Lamas; Kerry L Lee; Michael O Sweeney; Russell Silverman; Angel Leon; Raymond Yee; Roger A Marinchak; Greg Flaker; Eleanor Schron; E John Orav; Anne S Hellkamp; Stephen Greer; John McAnulty; Kenneth Ellenbogen; Frederick Ehlert; Roger A Freedman; N A Mark Estes; Arnold Greenspon; Lee Goldman
Journal:  N Engl J Med       Date:  2002-06-13       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.